Different Effects of Aspirin, Dipyridamole and UD-CG 115 on Platelet Activation in a Model of Vascular Injury: Studies with Extracellular Matrix Covered with Endothelial Cells

Summary

Cultured endothelial cells produce an extracellular matrix (ECM) which activates platelets, similarly to deendothelialized vascular segments. Platelet-rich plasma (PRP) was incubated with endothelial cells cultures seeded in various densities on ECM. The interaction of the platelets with this artifical intima was evaluated by phase microscopy and by thromboxane A2 (TXA₂) and prostacyclin (PGI₂) measurement. Large platelet aggregates were formed on exposed ECM. Platelets aggregation but not adhesion on the ECM was markedly inhibited by the presence of endothelial cells. Pretreatment of the endothelial cells with 0.1 mM aspirin reduced their PGI₂ synthesis and was associated with platelet aggregation on the ECM. 10 μM dipyridamole markedly inhibited platelet activation by ECM when the drug was added to citrated whole blood before PRP preparation. UD-CG 115 which elevates cyclic AMP in cardiac muscle, inhibited platelet aggregation and TXA₂ production induced by ECM, in the presence as well as in the absence of endothelial cells, without any effect on endothelial PGI₂ production.

Key words

Extracellular matrix - Endothelial cells - Platelets - Prostacyclin - Thromboxane A₂

• References

• 1 Gospodarowicz D, Vlodavsky I, Savion N. The extracellular matrix. Endocr Rev 1980; 1: 210-227
• 2 Gospodarowicz D, Vlodavsky I, Savion N. The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells. J Supramol Struc 1980; 13: 339-372
• 3 Vlodavsky I, Eldor A, Hy-Am E, Atzmon R, Fuks Z. Platelet interaction with the extracellular matrix produced by cultured endothelial cells; A model to study the thrombogenicity of isolated subendothelial basal lamina. Thromb Res 1982; 28: 179-191
• 4 Booyse FM, Feder S, Quarfoot A. Culture-produced subendothelium II. Effect of plasma, FVIII:vW and fibronectin on interaction of normal platelets with normal and von Willebrand porcine aortic subendothelium. Thromb Res 1982; 28: 299-311
• 5 Sakariassen KS, Aarts P AM M, De Groot PG, Houdijk W PM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
• 6 Eldor A, Vlodavsky I, Martinowicz U, Fuks Z, Coller BS. Platelet interaction with subendothelial extracellular matrix: Platelet-fibrino-gen interactions are essential for platelet aggregation but not for the matrix-induced release reaction. Blood 1985; 65: 1477-1483
• 7 Levine RF, Eldor A, Hy Am E, Gamliel H, Fuks Z, Vlodavsky I. Megakaryocyte interaction with subendothelial extracellular matrix is associated with adhesion, platelet-like shape change, and thromboxane A₂ production. Blood 1985; 66: 570-576
• 8 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
• 9 Eldor A, Falcone DJ, Hajjar DP, Minick CR, Weksler BB. Recovery of prostacyclin production of de-endothelialized rabbit aorta: Critical role of neointimal smooth muscle cells. J Clin Invest 1981; 67: 735-741
• 10 Tschopp TB, Baumgartner HR, Silberbauer K, Sinzinger H. Platelet adhesion and platelet thrombus formation on subendothelium of human arteries and veins exposed to flowing blood in vitro. A comparison with rabbit aorta. Hematostas 1979; 8: 19-29
• 11 Honerjager P, Heiss A, Schafer-Korting M, Schonsteiner G, Reiter M. UD-CG 115 - a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol 1984; 325: 259-269
• 12 Gospodarowicz D, Moran J, Braun D, Birdwell C. Clonal growth of bovine vascular endothelial cells: Fibroblast growth factor as a survival agent. Proc Natl Acad Sci USA 1976; 73: 4120-4124
• 13 Gospodarowicz D, Mescher AR, Birdwell CR. Stimulation of comeal endothelial cell proliferation in vitro by fibroblast and epidermal growth factors. Exp Eye Res 1977; 25: 75-89
• 14 Eldor A, Zylber KatzE, Levy M. The effect of oral administration of dipyrone on the capacity of blood platelets to synthesize thromboxane A₂ in man. Eur J Clin Pharm 1984; 26: 171-176
• 15 Boenziger NC, Becherer PR, Majerus PW. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell 1974; 16: 967-974
• 16 Weiss HJ, Turritto VT. Prostacyclin (PGI₂) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 1979; 53: 244-259
• 17 Adelman B, Stemerman MB, Menuell D, Handin RI. The interaction of platelets with aortic subendothelium: Inhibition of adhesion and secretion by prostaglandin I₂ . Blood 1981; 58: 198-205
• 18 Buchanan MR, Dejana E, Gent M, Mustard JF, Hirsch J. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment. J Clin Invest 1981; 67: 503-508
• 19 Levin RI, Weksler BB, Marcus AJ, Jaffe EA. Prostacyclin production by endothelial cells. In: Biology of endothelial cells Jaffe EA. (ed) 228-246 Martinus Nijhoff; Boston: 1984
• 20 Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913
• 21 Needleman P, Wyche A, Raz A. Platelet and blood vessel arachido-nate metabolism and interactions. J Clin Invest 1979; 63: 345-377
• 22 Homsta G, Haddeman E, Don JA. Blood platelets do not provide endoperoxides for vascular prostacyclin production. Nature 1979; 279: 66-68
• 23 Marcus A, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-986
• 24 Packham MA, Mustard JF. Nonsteroidal anti-inflammatory drugs, pyrimido-pyrimidine components and tricyclic compounds. Effect on platelet function. In: Platelets, Drugs and Thrombosis Hirsch J, Cade JF, Gallus AS, Schonbaum E. (eds) 111-123 Karger; Basel: 1975
• 25 Gresele P, Zoja C, Deckmyn H, Amout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemostas 1983; 50: 852-856
• 26 Masotti G, Poggesi L, Galanti G, Neri-Semeri GG. Stimulation of prostacyclin by dipyridamole. Lancet 1979; 2: 1412
• 27 Blass KE, Block HU, Forster W, Ponich K. Dipyridamole: A potent stimulator of prostacyclin (PGI₂) biosynthesis. Br J Pharmacol 1980; 68: 71-73
• 28 Moncada S, Korbut K. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1287
• 29 Di Minno G, Silver MJ, De Gaetano G. Ingestion of dipyridamole reduces inhibitory effect of prostacyclin of human platelets. Lancet 1979; 2: 701-702
• 30 Gresele P, Amout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemostas 1986; 55: 12-18
• 31 Baumgartner HR. Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. Haemostas 1979; 8: 340-352
• 32 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Effect of aspirin and dipyridamole on the interaction of human platelets with subendothelium: Studies using citrated and native blood. Thromb Haemostas 1981; 45: 136-141
• 33 Yahalom J, Eldor A, Fuks Z, Voldavsky I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 1984; 74: 1842-1848
• 34 Vlodavsky I, Fuks Z, Bar Ner M, Yahalom J, Eldor A, Savion N, Naparstek Y, Cohen IR, Kramer M, Schirrmacher V. Degradation of heparan sultate in the subendothelial basement membrane by normal and malignant cells. In: Extracellular Matrix; Structure and Function Reddi RH. (Ed.), pp. 283-308 Alan R Liss; NY: 1985